Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

Hyperreflective retinal foci as predictive biomarkers for fluid resolution after dexamethasone implant treatment in retinal vein occlusions. (PubMed, Eye (Lond)) - "Baseline i-HRF count may serve as a potentially valuable biomarker of fluid resolution after DEX-I in retinal vein occlusions. Higher i-HRF counts may be associated with a greater likelihood of SRF resolution within a dexamethasone-treated cohort."

Biomarker • Journal • Retinal Disorders • Retinal Vein Occlusion

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Hackensack Meridian Health | Suspended ➔ Recruiting | Trial completion date: Feb 2027 ➔ Feb 2028 | Trial primary completion date: Feb 2027 ➔ Feb 2028

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=28 | Active, not recruiting | Sponsor: University of Rochester | Trial completion date: Jul 2026 ➔ Sep 2027 | Trial primary completion date: Jul 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Local therapy in uveitis: Current concepts and emerging strategies. (PubMed, Indian J Ophthalmol) - "Topical corticosteroids remain first-line for anterior uveitis, while periocular and intravitreal injections such as triamcinolone acetonide and dexamethasone implants (Ozurdex®) are effective for intermediate and posterior disease. Long-acting fluocinolone acetonide implants (Retisert®, Yutiq®) offer sustained control for chronic or recurrent cases, though ocular hypertension and cataract formation are common. The introduction of suprachoroidal corticosteroid delivery (Xipere®) allows precise posterior segment targeting with fewer anterior complications. Nonsteroidal intravitreal agents, including methotrexate and sirolimus, serve as steroid-sparing options, and topical immunomodulators such as cyclosporine and tacrolimus can be rarely used in chronic anterior uveitis. Emerging modalities like intravitreal biologics, nanocarrier systems, and gene-based delivery hold promise for long-term disease modulation. A tailored, evidence-based approach to..."

Journal • Cardiovascular • Cataract • Glaucoma • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

Dexamethasone Sustained-Release Implant Enhances Early Visual Recovery Following Minimally Invasive Vitrectomy for Idiopathic Epiretinal Membrane: A Retrospective Cohort Study. (PubMed, Curr Med Chem) - "Intraoperative DEX-SR implantation was associated with accelerated early anatomical and functional recovery in this retrospective cohort, with a tolerable safety profile. Prospective randomized trials are needed to confirm these preliminary findings."

Journal • Retrospective data • Inflammation • Macular Edema • Ophthalmology • Retinal Disorders

BETTIS-1: EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=75 | Active, not recruiting | Sponsor: Eclipse Life Sciences, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Correlation between the optical density ratio of subretinal fluid in OCT images and visual outcome in eyes with diabetic MacularEdema. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In DME patients with SRD, patients with a lower baseline subretinal fluid ODR had better visual quality recovery after the anti-VEGF drug or steroid hormone treatment, identifying the optical density in subretinal fluid as a clinically relevant biomarker in diabetic macularedema."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX) (clinicaltrials.gov) - P2 | N=53 | Completed | Sponsor: Hospices Civils de Lyon | Active, not recruiting ➔ Completed

Trial completion • Diabetic Macular Edema • Ophthalmology

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (clinicaltrials.gov) - P=N/A | N=236 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026 | Trial primary completion date: Dec 2026 ➔ Aug 2026

Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Dexamethasone intravitreal implant (Ozurdex) monotherapy for uveitic macular edema secondary to non-infectious uveitis: a single-center retrospective cohort study. (PubMed, Int Ophthalmol) - "In this selected real-world cohort, dexamethasone implant monotherapy was associated with significant anatomical improvement and early functional improvement, with high 12 month follow-up completeness. The initial implant provided a clinically useful but time-limited treatment effect, and repeat implantation was required in a subset of eyes. These findings support dexamethasone implant as a local treatment strategy for selected patients with uveitic macular edema while emphasizing the need for monitoring of ocular steroid-related adverse effects and individualized long-term inflammatory management."

Journal • Monotherapy • Retrospective data • Review • Cataract • Glaucoma • Immunology • Inflammation • Inflammatory Arthritis • Macular Edema • Ocular Inflammation • Ophthalmology • Psoriatic Arthritis • Rheumatology • Sarcoidosis • Seronegative Spondyloarthropathies • Uveitis

LODEXA: Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: University of California, San Diego

New P2 trial • Eye Cancer • Inflammation • Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Twelve‑month Response and Safety of Intravitreal Dexamethasone Implant in Treatment‑Naïve and Recalcitrant Cystoid Macular Edema Secondary to Branch Retinal Vein Occlusion (TREAT-BRVO Study). (PubMed, Clin Ophthalmol) - "To compare anatomical and visual outcomes following dexamethasone intravitreal implant (Ozurdex) in treatment-naive versus recalcitrant cystoid macular edema (CME) secondary to branch retinal vein occlusion (BRVO). Intravitreal dexamethasone implant was associated with significant anatomical and functional improvements in both treatment-naïve and anti-VEGF refractory BRVO-related CME. While no statistically significant differences were identified between the groups, adequately powered prospective studies are required to determine whether treatment outcomes differ according to prior anti-VEGF exposure."

Journal • Cataract • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Intracapsular Ozurdex® implant fixation : When the depot chooses its own location (PubMed, Ophthalmologie) - No abstract available

Journal

Intraocular Pressure Elevation After Suprachoroidal Triamcinolone Acetonide in Noninfectious Uveitis: An IRIS® Registry Study. (PubMed, Ophthalmol Glaucoma) - "In this large real-world cohort of patients with NIU, both SCS-TA and DEX were associated with higher risks of clinically significant IOP elevation compared with systemic therapy controls, with broadly similar incidence between the two CS delivery approaches. Although IOP-lowering medications were more frequently required, the overall incidence of glaucoma surgery remained low."

Journal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Study of Clinical Observation and Mechanism of Conbercept Combined with Dexamethasone Intravitreal Implant in the Treatment of Refractory Macular Edema (ChiCTR) - P4 | N=60 | Recruiting | Sponsor: Shenzhen University General Hospital; Shenzhen University General Hospital

New P4 trial • Macular Edema • Ophthalmology

Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS® Registry Analysis. (PubMed, Am J Ophthalmol) - "The incidence of post-injection endophthalmitis is greater with corticosteroid implants and anticomplement therapies. Heightened aseptic vigilance may be warranted with injections that necessitate larger gauge needles, modulate the immune response and/or are prepared from a vial."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics

A real-world study of Faricimab: efficacy and biomarkers in treatment-experienced neovascular age-related macular degeneration(nAMD) and diabetic macular edema (DME) patients. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In a real-world setting, intravitreal faricimab demonstrated a favorable safety profile and robust anatomical response in treating treatment-experienced nAMD and DME. However, the anatomical response was stronger than the visual gain in these treatment-experienced eyes, which often have limited visual potential."

Biomarker • Journal • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Jun 2029

Trial completion date • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology

Postoperative cystoid macular edema after pars plana vitrectomy for epiretinal membrane: incidence, anatomical and functional outcomes, and response to intravitreal dexamethasone implant. (PubMed, Int J Retina Vitreous) - "Postoperative CME requiring treatment occurred in approximately 1 in 11 eyes following PPV with ERM peeling and was associated with significant anatomical and functional impairment. The present findings suggest that intravitreal dexamethasone implant was associated with improvement in selected cases of postoperative CME without additional impact on IOP; however, larger prospective studies are required to confirm these results."

Journal • Macular Edema • Ophthalmology • Retinal Disorders

Real-world outcomes of naïve, early switch and late switch eyes treated with dexamethasone intravitreal implant for retinal vein occlusion. (PubMed, Eur J Ophthalmol) - "However, baseline BCVA emerged as the main independent determinant of functional response, suggesting that visual outcomes are primarily driven by initial visual status rather than switching timing. By including a naïve comparison group, this study provides novel insights into the management of ME-RVO in patients with suboptimal anti-VEGF response."

Journal • Real-world evidence • Macular Edema • Ophthalmology • Retinal Vein Occlusion

A two-step approach for suprachoroidal delivery of dexamethasone implant using a custom-made injector. (PubMed, Int J Retina Vitreous) - "This two-step technique for suprachoroidal Ozurdex delivery using a custom‑made injector with viscoelastic pre‑injection is feasible and showed no major safety concerns in this case. It may provide an alternative delivery method for selected patients with non‑infectious macular edema who have relative contraindications to intravitreal anti‑vascular endothelial growth factor (VEGF) or corticosteroid injections. Further studies are needed to establish safety and efficacy."

Journal • Cataract • Diabetic Macular Edema • Diabetic Retinopathy • Hematological Disorders • Macular Edema • Ophthalmology • Retinal Disorders

Sequential Intravitreal Corticosteroid Rescue Including Ozurdex After Anti-VEGF Failure in Bilateral Uveitic Cystoid Macular Edema With Asymmetric Relapse. (PubMed, Cureus) - "Treatment was then changed to bilateral intravitreal triamcinolone acetonide, after which substantial visual and anatomical improvement was observed in both eyes...This case demonstrates that bilateral uveitic CME refractory to anti-VEGF therapy may show limited response to repeated anti-VEGF treatment but substantial anatomical and functional improvement after sequential intravitreal corticosteroid therapy. It also highlights the relapsing and asymmetric course of inflammatory macular edema and the importance of individualized retreatment and close optical coherence tomography (OCT)-based monitoring."

Journal • Inflammation • Macular Edema • Ophthalmology

Selective laser trabeculoplasty is effective in controlling steroid-induced OHT after 0.19 µg Fluocinolone acetonide implant, a long-term outcome of 15 eyes. (PubMed, BMC Ophthalmol) - "SLT is a safe, effective, and repeatable intervention for preventing or controlling IOP elevation in OHT responders' eyes receiving FAc implants. Performing SLT prior to FAc injection may offer better IOP control and reduce variability in such patients."

Journal • Cardiovascular • Glaucoma • Macular Edema • Ophthalmology

Drusen-Like Deposit Choroidopathy in Systemic Lupus Without Glomerulonephritis Treated With a Dexamethasone Implant. (PubMed, Cureus) - "The ocular findings were subsequently reclassified as inflammatory choroiditis associated with DLDs, without evidence of lupus nephritis. Treatment with systemic corticosteroids, mycophenolate mofetil, and dexamethasone intravitreal implant in the LE resulted in progressive clinical improvement."

Journal • Age-related Macular Degeneration • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Macular Degeneration • Macular Edema • Nephrology • Ocular Inflammation • Ophthalmology • Retinal Disorders • Systemic Lupus Erythematosus • Wet Age-related Macular Degeneration

Intravitreal dexamethasone sodium phosphate challenge to predict implant response in refractory diabetic macular edema: a pilot study. (PubMed, Arq Bras Oftalmol) - "A short-term dexamethasone sodium phosphate challenge is a safe, low-cost, and highly specific predictor of dexamethasone implant efficacy. This "test-and-treat" strategy may optimize resource allocation in resource-constrained settings by identifying responders before high-cost implantation."

Journal • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology